| Identification | Back Directory | [Name]
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | [CAS]
141388-76-3 | [Synonyms]
Besivence
Besivance
Besifloxacin
Besifloxacin USP/EP/BP
3-Quinolinecarboxylicacid,7-[(3R)-3-aMinohexahydro-1H-azepin-1-y
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-qu
(R)-7-(3-aMinoazepan-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
7-[(3R)-3-Amino-1-azepanyl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinolinecarboxylic acid
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
3-Quinolinecarboxylic acid, 7-[(3R)-3-aMinohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-
(R)-7-(3-Aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid USP/EP/BP | [EINECS(EC#)]
604-773-0 | [Molecular Formula]
C19H21ClFN3O3 | [MDL Number]
MFCD00917502 | [MOL File]
141388-76-3.mol | [Molecular Weight]
393.844 |
| Chemical Properties | Back Directory | [Boiling point ]
607.0±55.0 °C(Predicted) | [density ]
1.469 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: Insoluble; | [pka]
6.41±0.50(Predicted) | [Water Solubility ]
Water: Insoluble |
| Hazard Information | Back Directory | [Chemical Properties]
Yellow to slightly yellow crystalline powder | [Definition]
ChEBI: Besifloxacin is a member of quinolines. | [Pharmaceutical Applications]
An amino-azepinyl quinolone formulated as a suspension for ophthalmic usage. It exhibits good antistaphylococcal activity, as well as activity against Str. pneumoniae, Enterobacteriaceae, H. influenzae and Mor. catarrhalis. It is weakly active against Corynebacterium spp. and has no useful activity against Ps. aeruginosa. After instillation into the eye, less than 0.1% of the drug reaches the plasma. It is used for bacterial conjunctivitis. | [Enzyme inhibitor]
This fourth-generation, fluoroquinolone-class antibi?otic (FW = 393.84
g/mol; CAS 141388-76-3), also known as Besivance, BOL-303224-A,
SS734, and 7-[ (3R) -3-aminoazepam-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid, displays activity in in vitro
antimicrobial efficacy studies as well as efficacy in an in vivo murine
infection model. BOL-303224-A demonstrates excellent ocular
pharmacokinetics in rabbits, with ocular mean residence times >7 hours,
reaching conjunctival concentrations that exceed the MIC90 for nonresistant
ophthalmic isolates for >12 hours following a single dose. Besifloxacin
acts as an anti-inflammatory agent in monocytes in vitro, a property that
may enhance its efficacy in ocular infections. It exhibits broad-spectrum
in vitro activity against aerobic and anaerobic bacteria, based on studies on
2,690 clinical isolates representing 40 species. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|